AIM: To develop a SULT1A1 multiplex ligation-dependent probe amplification assay and to investigate multi-ethnic copy number variant frequencies. METHODS: A novel multiplex ligation-dependent probe amplification assay was developed and tested on 472 African-American, Asian, Caucasian, Hispanic and Ashkenazi Jewish individuals. RESULTS: The frequencies of atypical total copy number (i.e., greater or less than two) were 38.7% for Hispanics, 38.9% for Ashkenazi Jewish, 43.2% for Caucasians, 53.6% for Asians and 64.1% for African-Americans. Heterozygous SULT1A1 deletion carriers (slow sulfators) were most common among Caucasians (8.4%), whereas African-Americans had the highest frequencies of three or more copies (rapid sulfators; 60.9%). CONCLUSION: Different ethnic and racial populations have varying degrees of SULT1A1-mediated sulfation activity, which warrants further research and that may have utility for drug response prediction among SULT1A1-metabolized medications.
AIM: To develop a SULT1A1 multiplex ligation-dependent probe amplification assay and to investigate multi-ethnic copy number variant frequencies. METHODS: A novel multiplex ligation-dependent probe amplification assay was developed and tested on 472 African-American, Asian, Caucasian, Hispanic and Ashkenazi Jewish individuals. RESULTS: The frequencies of atypical total copy number (i.e., greater or less than two) were 38.7% for Hispanics, 38.9% for Ashkenazi Jewish, 43.2% for Caucasians, 53.6% for Asians and 64.1% for African-Americans. Heterozygous SULT1A1 deletion carriers (slow sulfators) were most common among Caucasians (8.4%), whereas African-Americans had the highest frequencies of three or more copies (rapid sulfators; 60.9%). CONCLUSION: Different ethnic and racial populations have varying degrees of SULT1A1-mediated sulfation activity, which warrants further research and that may have utility for drug response prediction among SULT1A1-metabolized medications.
Authors: Ann M Moyer; Vera J Suman; Richard M Weinshilboum; Rajeswari Avula; John L Black; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; James N Ingle; Matthew P Goetz Journal: Pharmacogenomics Date: 2011-10-03 Impact factor: 2.533
Authors: Susan Nowell; Carol Sweeney; Maria Winters; Angie Stone; Nicholas P Lang; Laura F Hutchins; Fred F Kadlubar; Christine B Ambrosone Journal: J Natl Cancer Inst Date: 2002-11-06 Impact factor: 13.506
Authors: Jacob A Tennessen; Abigail W Bigham; Timothy D O'Connor; Wenqing Fu; Eimear E Kenny; Simon Gravel; Sean McGee; Ron Do; Xiaoming Liu; Goo Jun; Hyun Min Kang; Daniel Jordan; Suzanne M Leal; Stacey Gabriel; Mark J Rieder; Goncalo Abecasis; David Altshuler; Deborah A Nickerson; Eric Boerwinkle; Shamil Sunyaev; Carlos D Bustamante; Michael J Bamshad; Joshua M Akey Journal: Science Date: 2012-05-17 Impact factor: 47.728
Authors: Susan A Nowell; Jiyoung Ahn; James M Rae; Joshua O Scheys; Andrew Trovato; Carol Sweeney; Stewart L MacLeod; Fred F Kadlubar; Christine B Ambrosone Journal: Breast Cancer Res Treat Date: 2005-06 Impact factor: 4.872
Authors: Mariana R Botton; Xingwu Lu; Geping Zhao; Elena Repnikova; Yoshinori Seki; Andrea Gaedigk; Eric E Schadt; Lisa Edelmann; Stuart A Scott Journal: Hum Mutat Date: 2019-11 Impact factor: 4.878
Authors: Emily J Koubek; Andrew T Ralya; Thomas R Larson; Renee M McGovern; Sarah A Buhrow; Joseph M Covey; Alex A Adjei; Naoko Takebe; Matthew M Ames; Matthew P Goetz; Joel M Reid Journal: J Clin Pharmacol Date: 2022-04-19 Impact factor: 2.860